Abstract
Historically, radiation oncologists have approached re-irradiating brain tumours with caution due to the potential risks of central nervous system late toxicity, especially radionecrosis, which may occur months or years following treatment. There is, however, a paucity of prospective data addressing this approach. Re-irradiation of brain tumours is attracting more interest as our understanding of the tolerance of the brain to radiation evolves. Furthermore, developments in radiation treatment approaches, technology and imaging enable highly accurate targeting of biologically relevant tumour volumes. Thanks to recent advancements in molecular-targeted therapy, further exploration of the role of re-irradiation – primary or in combination with novel agents – is needed.
The original version of this chapter was revised. An erratum to this chapter can be found at 10.1007/978-3-319-41825-4_78.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ang K, Jiang GL, Feng Y (2001) Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 50:1013–1020
Arcicasa M, Roncadin M, Bidoli E et al (1999) Re-irradiation and lomustine in patients with relapsed high grade gliomas. Int J Radiat Oncol Biol Phys 43:789–793
Armstrong TS, Wefel JS, Wang M et al (2013) Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 31:4076–4084
Bobek-Billewicz B, Stasik-Pres G, Majchrzak H (2010) Differentiation between brain tumour recurrence and radiation injury using perfusion, diffusion-weighted imaging and MR spectroscopy. Folia Neuropathol 48:81–92
Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461
Brem H, Piantadosi S, Burger PC et al (1995) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012
Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477
Carson K, Grossman S, Fisher J (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumour therapy CNS consortium phase I and phase II clinical trials. J Clin Oncol 25:2601–2606
Champ CE, Palmer JD, Volek JS et al (2014) Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol 117:125–131
Chan JL, Lee SW, Fraass BA (2002) Survival and failure patterns of high grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642
Chen W (2007) Clinical applications of PET in brain tumours. J Nucl Med 48:1468–1481
Cho KH, Hall WA, Gerbi BJ et al (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent gliomas. Int J Radiat Oncol Biol Phys 45:1133–1141
Chu HH, Choi SH, Ryoo I et al (2013) Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 269:831–840
Clark GM, McDonald AM, Nabors LB et al (2014) Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neuro Oncol Pract 1:172–177
Combs SE, Widmer V, Thilman C et al (2005a) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme. Cancer 104:2168–2173
Combs SE, Thilmann C, Edler L et al (2005b) Efficacy of fractionated stereotactic re-irradiation in recurrent gliomas: long term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869
Combs S, Debus J, Schulz-Ertner D (2007) Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 7:167
Combs S, Bischof M, Welzel T (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89:205–210
Combs SE, Bruckner T, Mizoe JE et al (2013a) Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis. Radiother Oncol 108:132–135
Combs SE, Edler L, Rausch R et al (2013b) Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 52:147–152
Cuneo KC, Vredenburgh JJ, Sampson JH et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018–2024
Darakchiev B, Albright R, Breneman J (2008) Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme. J Neurosurg 108:236–242
Fabrini MG, Perrone F, De Franco L et al (2009) Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas. Strahlenther Onkol 185:524–529 (erratum:703)
Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053
Fokas E, Wacker U, Gross MW et al (2009) Hypofractionated stereotactic re-irradiation of recurrent glioblastomas: a beneficial treatment option after high dose radiotherapy. Strahlenther Onkol 185:235–240
Gabayan AJ, Green SB, Sanan A et al (2006) Gliasite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 58:701–709
Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57
Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
Götz I, Grosu AL (2013) [(18)F]FET-PET imaging for treatment and response monitoring of radiation therapy in malignant glioma patients – a review. Front Oncol 3:104
Grosu A, Weber W, Franz M et al (2005) Re-irradiation of recurrent high grade gliomas using amino acid PET (SPECT)/CT/MRI fusion to determine gross tumour volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519
Gutin P, Iwamoto F, Beal K et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163
Hall EJ, Giaccia AJ (2005) Radiobiology for the radiologist, 6th edn. Lippincott Williams and Wilkins, Philadelphia
Hess CF, Schaaf JC, Kortmann RD et al (1994) Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146–149
Hudes RS, Corn BW, Werner-Wasik M et al (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43:293–298
Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 18:1303–1311
Kong DS, Lee JI, Park K et al (2008) Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 112:2046–2051
Koshi K, Yamamoto H, Nakahara A et al (2007) Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J Neurooncol 82:297–303
Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumour from radiation injury. J Nucl Med 41:1861–1867
Lederman G, Wronski M, Arbit E (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159
Levin VA, Bidaut L, Hou P et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495
Macdonald D, Cascino T, Schold SJ et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Martuscello RT, Vedam-Mai V, McCarthy DJ et al. (2015) A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res 22:2482–2495
Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70:1350–1360
Ngyuen QT, Tsien RY (2013) Fluorescence-guided surgery with live molecular navigation — a new cutting edge. Nat Rev Cancer 13:653–662
Nieder C, Adam M, Molls M et al (2006) Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 60:181–193
Nieder C, Astner ST, Mehta MP et al (2008) Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am J Clin Oncol 31:300–305
Osman MA (2014) Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas. Ann Transl Med 2:44
Palmer JD, Siglin J, Yamoah K et al (2015) Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. J Neurooncol 124:215–221
Patel M, Siddiqui F, Jin J-Y et al (2009) Salvage re-irradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185–191
Quick-Weller J, Lescher S, Forster MT et al (2016) Combination of 5-ALA and iMRI in re-resection of recurrent glioblastoma. Br J Neurosurg 8:1–5
Rieger J, Bahr O, Maurer GD et al (2014) ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol 44:1843–1852
Sampson JH, Vlahovic G, Sahebjam S et al. (2015) Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. J Clin Oncol ASCO Ann Meet Proc 33(3010S)
Scharfen CO, Sneed PK, Wara WM et al (1992) High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 24:583–591
Schuster J, Lai RK, Recht LD et al (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861
Schwer A, Damek D, Kavanagh B et al (2008) A phase I dose escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 70:993–1001
Shepherd S, Laing R, Cosgrove V et al (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37:393–398
Shi W, Palmer JD, Werner-Wasik M et al. (2016) Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. J Neurooncol 127:535–539
Shrieve DC, Alexander E 3rd, Wen PY et al (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275–282
Sneed PK, McDermott MW, Gutin PH (1997) Interstitial brachytherapy procedures for brain tumours. Semin Surg Oncol 13:157–166
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase II study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1199–1208
Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma. JAMA 314:2535–2543
Surapaneni K, Kennedy BC, Yanagihara TK et al (2015) Early cerebral blood volume changes predict progression after convection-enhanced delivery of topotecan for recurrent malignant glioma. World Neurosurg 84:163–172
Taphoorn MJ, Henriksson R, Bottomley A et al (2015) Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 33:2166–2175
Tofilon P, Fike J (2000) The radioresponse of the central nervous system: a dynamic process. Radiat Res 153:357–370
Torcuator R, Zuniga R, Mohan YS (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63–68
Tselis N, Kolotas C, Birn G et al (2007) CT guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long term results. Strahlenther Onkol 183:563–570
Ullrich RT, Kracht LW, Jacobs AH (2008) Neuroimaging in patients with gliomas. Semin Neurol 28:484–494
Weller M, Tabatabai G, Kästner B et al (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res 21:2057–2064
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Westphal M, Lamszus K (2015) Circulating biomarkers for gliomas. Nat Rev Neurol 11:556–566
Wick W, Steinbach JP, Kuker WM et al (2004) One week on/one week off: a novel active regime of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115
Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357–3361
Withers HR (1985) Biological basis for altered fractionation schemes. Cancer 55:2086–2095
Wong CS, van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4:273–284
Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled into phase II clinical trials. J Clin Oncol 17:2572–2579
Wong E, Huberman M, Lu X-Q (2008) Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 26:5049
Wong CS, Fehlings MG, Sahgal A (2015) Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord 53:574–580
Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicentre phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumour Group. J Clin Oncol 17:2762–2771
Acknowledgement
Susan C. Short and Jennifer E. Gains authored the brain tumours chapter for the first edition of this textbook. The present chapter is based on their updated manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Palmer, J.D., Champ, C., Short, S.C., Fogh, S.E. (2016). Brain Tumours. In: Nieder, C., Langendijk, J. (eds) Re-Irradiation: New Frontiers. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2016_66
Download citation
DOI: https://doi.org/10.1007/174_2016_66
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41823-0
Online ISBN: 978-3-319-41825-4
eBook Packages: MedicineMedicine (R0)